Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1995-05-31
1996-10-22
O'Sullivan, Peter
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
546 77, A61K 3144, C07D22118
Patent
active
055677088
ABSTRACT:
17.beta.-N-monosubstituted-carbamoyl-4-5.alpha.-androst-1-en-3-ones of the formula ##STR1## wherein R.sup.1 is selected from hydrogen, methyl and ethyl and R.sup.2 is a branched chain alkyl of from 3-12 carbons, and R', R", R"' are hydrogen or methyl are active as testosterone 5.alpha.-reductase inhibitors and thus are useful topically for treatment of androgenic alopecia.
REFERENCES:
Diani et al., "Main Growth Effects of Oral Administration of Finastindi, etc." J. Clinical Endocrinology and Metobolism vol. 74, No. 2, pp. 345-350.
Brooks, J. R. "Prostatic Effects Induced in Dogs by Chronic or Acute Oral Administration of 5 .alpha. Reductase Inhibitors", The Prostate 9:65-75 (1986).
Rasmusson Gary H.
Reynolds Glenn F.
Merck & Co. , Inc.
O'Sullivan Peter
Quagliato Carol S.
Tribble Jack L.
Winokur Melvin
LandOfFree
Methods of treating androgenic alopecia with finasteride [17.bet does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of treating androgenic alopecia with finasteride [17.bet, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of treating androgenic alopecia with finasteride [17.bet will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2358848